Physician
Casey County Hospital District
Casey County Hospital District was paid $11.12M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoCASEY COUNTY HOSPITAL DISTRICT
LIBERTY, KY 42539
LIBERTY, KY 42539
33aNPI1407829567assigned 02/09/2006
33bProvider typeEmergency Medical Services (Emergency Medicine) Physician
28Total paid$11.12M
24GClaims215,909
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,732 | $1.40M | |
| 2019 | 30,647 | $1.36M | |
| 2020 | 25,268 | $1.07M | |
| 2021 | 36,078 | $1.66M | |
| 2022 | 37,399 | $2.03M | |
| 2023 | 31,958 | $1.96M | |
| 2024incomplete | 22,827 | $1.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 19,863 | 17,816 | $2.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 8,797 | 7,682 | $1.26M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.7% | 1,523 | 1,258 | $636K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.5% | 2,636 | 2,219 | $611K |
| 71046 | Radiologic examination, chest; 2 views | 5.3% | 9,026 | 6,994 | $595K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.6% | 9,301 | 7,646 | $509K |
| 80053 | Comprehensive metabolic panel | 4.4% | 12,182 | 10,461 | $490K |
| 71045 | Radiologic examination, chest; single view | 3.0% | 9,106 | 5,423 | $334K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 1,389 | 1,164 | $315K |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 36,590 | 17,640 | $291K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.6% | 3,730 | 3,030 | $285K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 11,444 | 9,766 | $263K |
93 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,335 | $181K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 3,498 | $173K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 1,643 | $170K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.4% | 8,105 | $158K |
| 80306 | 1.3% | 4,710 | $148K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 860 | $142K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 3,142 | $133K |
| 80061 | Lipid panel | 1.2% | 2,529 | $130K |
| 87276 | 1.1% | 5,423 | $119K | |
| 87275 | 1.0% | 5,446 | $115K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,827 | $100K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 747 | $98K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,327 | $97K |
| 72100 | <1% | 1,084 | $94K | |
| 84484 | <1% | 2,607 | $92K | |
| 73562 | <1% | 826 | $90K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 690 | $74K |
| 73630 | <1% | 902 | $72K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 303 | $67K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,701 | $63K |
| 71250 | <1% | 128 | $62K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 733 | $56K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 813 | $52K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,895 | $49K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 614 | $49K |
| 83690 | <1% | 1,947 | $48K | |
| 81001 | <1% | 3,714 | $48K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,384 | $45K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 448 | $43K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 464 | $42K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 499 | $40K |
| 82607 | <1% | 570 | $39K | |
| 74018 | <1% | 644 | $38K | |
| 82150 | <1% | 1,842 | $36K | |
| 83735 | <1% | 1,400 | $33K | |
| 87081 | <1% | 3,577 | $33K | |
| 73610 | <1% | 391 | $31K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,069 | $29K |
| 85027 | <1% | 1,633 | $29K | |
| 73030 | <1% | 298 | $27K | |
| 84439 | <1% | 1,080 | $25K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 529 | $24K |
| 82550 | <1% | 712 | $23K | |
| 73130 | <1% | 196 | $19K | |
| 81025 | <1% | 634 | $18K | |
| 87186 | <1% | 347 | $16K | |
| 87807 | <1% | 475 | $13K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 31 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 204 | $12K |
| 83880 | <1% | 290 | $11K | |
| 82553 | <1% | 342 | $11K | |
| 94664 | <1% | 362 | $10K | |
| 84703 | <1% | 269 | $9K | |
| 82652 | <1% | 58 | $8K | |
| 85610 | <1% | 441 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 244 | $7K |
| 93971 | <1% | 47 | $7K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 91 | $6K |
| 81002 | <1% | 707 | $5K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 79 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 654 | $5K |
| 87040 | <1% | 96 | $4K | |
| 72040 | <1% | 31 | $4K | |
| 80349 | <1% | 330 | $4K | |
| 96367 | <1% | 38 | $3K | |
| 83605 | <1% | 54 | $3K | |
| 87280 | <1% | 127 | $2K | |
| 94760 | <1% | 109 | $2K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 2,176 | $2K |
| 82803 | <1% | 21 | $2K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 40 | $2K |
| 85379 | <1% | 113 | $2K | |
| 85652 | <1% | 192 | $2K | |
| 85730 | <1% | 72 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 393 | $2K |
| 81003 | <1% | 235 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 76 | $1K |
| 0011A | <1% | 49 | $1K | |
| 96368 | <1% | 27 | $1K | |
| 0012A | <1% | 42 | $1K | |
| 80324 | <1% | 128 | $821.35 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 131 | $740.54 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 46 | $696.90 |
| 80348 | <1% | 37 | $498.88 | |
| 36600 | <1% | 20 | $482.29 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $339.30 |
| 80346 | <1% | 13 | $291.00 | |
| 86308 | <1% | 24 | $232.20 | |
| 80361 | <1% | 31 | $200.09 | |
| 85651 | <1% | 19 | $171.74 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 19 | $170.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14 | $155.40 |
| 80305 | <1% | 45 | $13.78 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTUNGATE, REX (CEO ADMINITSTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Jane Todd Crawford Memorial Hospital INC. | Greensburg, KY | $7.65M |
| Casey County Hospital District | Liberty, KY | $1.34M |
| Jane Todd Crawford Memorial Hospital, INC. | Greensburg, KY | $1.33M |
| Casey County Hospital District | Liberty, KY | $1.04M |
| Jane Todd Crawford Memorial Hospital, INC. | Greensburg, KY | $590K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.